Floatz logo

Tildacerfont

Congenital Adrenal Hyperplasia

Spruce BiosciencesSmall moleculePhase 2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Congenital Adrenal Hyperplasia cohort.

Asset / SponsorPhaseRating
Solu-Cortef
University of Texas Southwestern Medical Center
Phase 4A
Cortisone
Federico II University
Phase 4BBB
Atumelnant
Crinetics Pharmaceuticals Inc.
Phase 3BB
FLUDROCORTISONE
University of Texas Southwestern Medical Center
Phase 3BB
DEXAMETHASONE
Shanghai Jiao Tong University School of Medicine
Phase 4BB

View all 21 →

Same molecule, other indications

Tildacerfont is also rated in:

classic congenital adrenal hyperplasiaDormant
CC
Indicative ·
41 / 100
View asset →
classic congenital adrenal hyperplasia due to 21-hydroxylase deficiencyDormant
C
Indicative ·
38 / 100
View asset →
polycystic ovary syndromeDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →